Core Viewpoint - Zenas BioPharma, Inc. is facing a class action lawsuit due to allegations of materially false and misleading statements regarding its financial status and operations funding during its initial public offering in September 2024 [2]. Group 1: Allegations - The complaint claims that Zenas BioPharma overstated the duration it could fund its operations with existing cash and expected IPO proceeds [2]. - It is alleged that the public statements made by the defendants were materially false and misleading throughout the relevant period and were negligently prepared [2]. Group 2: Class Action Details - The class period for the lawsuit includes shareholders who purchased ZBIO securities during the time of the IPO [1]. - Shareholders are encouraged to register for the class action by June 16, 2025, to potentially be appointed as lead plaintiffs [3]. - Once registered, shareholders will receive updates on the case through a portfolio monitoring software [3]. Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].
Shareholders that lost money on Zenas BioPharma, Inc.(ZBIO) Urged to Join Class Action - Contact The Gross Law Firm to Learn More